207 related articles for article (PubMed ID: 17786301)
1. Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes.
Banno K; Yanokura M; Kawaguchi M; Kuwabara Y; Akiyoshi J; Kobayashi Y; Iwata T; Hirasawa A; Fujii T; Susumu N; Tsukazaki K; Aoki D
Int J Oncol; 2007 Oct; 31(4):713-20. PubMed ID: 17786301
[TBL] [Abstract][Full Text] [Related]
2. Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer.
Yanokura M; Banno K; Kawaguchi M; Hirao N; Hirasawa A; Susumu N; Tsukazaki K; Aoki D
Oncol Rep; 2007 Jan; 17(1):41-8. PubMed ID: 17143476
[TBL] [Abstract][Full Text] [Related]
3. Aberrant hypermethylation of the promoter region of the CHFR gene is rare in primary breast cancer.
Tokunaga E; Oki E; Nishida K; Koga T; Yoshida R; Ikeda K; Kojima A; Egashira A; Morita M; Kakeji Y; Maehara Y
Breast Cancer Res Treat; 2006 May; 97(2):199-203. PubMed ID: 16502017
[TBL] [Abstract][Full Text] [Related]
4. Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.
Li Z; Zhang H; Yang J; Hao T; Li S
Cell Biol Int; 2012 May; 36(5):427-32. PubMed ID: 21864295
[TBL] [Abstract][Full Text] [Related]
5. Aberrant promoter hypermethylation of the CHFR gene in oral squamous cell carcinomas.
Baba S; Hara A; Kato K; Long NK; Hatano Y; Kimura M; Okano Y; Yamada Y; Shibata T
Oncol Rep; 2009 Nov; 22(5):1173-9. PubMed ID: 19787237
[TBL] [Abstract][Full Text] [Related]
6. Association of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cells.
Masuda K; Banno K; Yanokura M; Tsuji K; Kobayashi Y; Kisu I; Ueki A; Yamagami W; Nomura H; Tominaga E; Susumu N; Aoki D
Oncol Rep; 2012 Oct; 28(4):1146-52. PubMed ID: 22797812
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of CHFR in nasopharyngeal carcinoma through promoter methylation.
Cheung HW; Ching YP; Nicholls JM; Ling MT; Wong YC; Hui N; Cheung A; Tsao SW; Wang Q; Yeun PW; Lo KW; Jin DY; Wang X
Mol Carcinog; 2005 Aug; 43(4):237-45. PubMed ID: 15937956
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer.
Satoh A; Toyota M; Itoh F; Sasaki Y; Suzuki H; Ogi K; Kikuchi T; Mita H; Yamashita T; Kojima T; Kusano M; Fujita M; Hosokawa M; Endo T; Tokino T; Imai K
Cancer Res; 2003 Dec; 63(24):8606-13. PubMed ID: 14695171
[TBL] [Abstract][Full Text] [Related]
9. Promoter hypermethylation and silencing of CHFR mitotic stress checkpoint gene in human gastric cancers.
Kang HC; Kim IJ; Park JH; Shin Y; Park HW; Ku JL; Yang HK; Lee KU; Choe KJ; Park JG
Oncol Rep; 2004 Jul; 12(1):129-33. PubMed ID: 15201973
[TBL] [Abstract][Full Text] [Related]
10. Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers.
Mizuno K; Osada H; Konishi H; Tatematsu Y; Yatabe Y; Mitsudomi T; Fujii Y; Takahashi T
Oncogene; 2002 Apr; 21(15):2328-33. PubMed ID: 11948416
[TBL] [Abstract][Full Text] [Related]
11. Small interfering RNA-induced CHFR silencing sensitizes oral squamous cell cancer cells to microtubule inhibitors.
Ogi K; Toyota M; Mita H; Satoh A; Kashima L; Sasaki Y; Suzuki H; Akino K; Nishikawa N; Noguchi M; Shinomura Y; Imai K; Hiratsuka H; Tokino T
Cancer Biol Ther; 2005 Jul; 4(7):773-80. PubMed ID: 16123600
[TBL] [Abstract][Full Text] [Related]
12. CHFR aberrant methylation involves a subset of human lung adenocarcinoma associated with poor clinical outcomes.
Koga T; Takeshita M; Ijichi K; Yano T; Maehara Y; Sueishi K
Hum Pathol; 2013 Jul; 44(7):1382-90. PubMed ID: 23415374
[TBL] [Abstract][Full Text] [Related]
13. CHFR gene is neither mutated nor hypermethylated in ovarian cancer.
Ludwig AH; Bujko M; Bidzinski M; Kupryjańczyk J
Cancer Detect Prev; 2007; 31(3):257-61. PubMed ID: 17673375
[TBL] [Abstract][Full Text] [Related]
14. [Study of mRNA expression level and hypermethylation of CHFR promoter in the laryngeal squamous cell carcinoma tissue].
He L; Ji W; Yang J; Zhao X
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Aug; 24(15):673-7. PubMed ID: 20942233
[TBL] [Abstract][Full Text] [Related]
15. Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer.
Brodie SA; Li G; Harvey D; Khuri FR; Vertino PM; Brandes JC
Oncotarget; 2015 Oct; 6(31):30773-86. PubMed ID: 26356822
[TBL] [Abstract][Full Text] [Related]
16. CHFR-associated early G2/M checkpoint defects in breast cancer cells.
Erson AE; Petty EM
Mol Carcinog; 2004 Jan; 39(1):26-33. PubMed ID: 14694445
[TBL] [Abstract][Full Text] [Related]
17. Promoter methylation of CHFR gene in gastric carcinoma tissues detected using two methods.
Cheng ZD; Hu SL; Sun YB; Xu WP; Shen G; Kong XY
Chin J Cancer; 2010 Feb; 29(2):163-6. PubMed ID: 20109344
[TBL] [Abstract][Full Text] [Related]
18. Aberrant methylation of the CHFR gene in advanced hepatocellular carcinoma.
Sakai M; Hibi K; Kanazumi N; Nomoto S; Inoue S; Takeda S; Nakao A
Hepatogastroenterology; 2005; 52(66):1854-7. PubMed ID: 16334792
[TBL] [Abstract][Full Text] [Related]
19. CHFR hypermethylation and EGFR mutation are mutually exclusive and exhibit contrastive clinical backgrounds and outcomes in non-small cell lung cancer.
Koga T; Takeshita M; Yano T; Maehara Y; Sueishi K
Int J Cancer; 2011 Mar; 128(5):1009-17. PubMed ID: 20473935
[TBL] [Abstract][Full Text] [Related]
20. CHFR suppression by hypermethylation sensitizes endometrial cancer cells to paclitaxel.
Wang X; Yang Y; Xu C; Xiao L; Shen H; Zhang X; Li T; Li X
Int J Gynecol Cancer; 2011 Aug; 21(6):996-1003. PubMed ID: 21792009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
